Currently, there are 63.96M common shares owned by the public and among those 63.08M shares have been available to trade.
The company’s stock has a 5-day price change of -0.81% and 14.26% over the past three months. CDMO shares are trading 88.62% year to date (YTD), with the 12-month market performance up to 88.33% higher. It has a 12-month low price of $5.65 and touched a high of $12.48 over the same period. CDMO has an average intraday trading volume of 1.85 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -0.37%, 5.85%, and 29.42% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Avid Bioservices Inc (NASDAQ: CDMO) shares accounts for 106.81% of the company’s 63.96M shares outstanding.
It has a market capitalization of $784.19M and a beta (3y monthly) value of 1.41. The earnings-per-share (ttm) stands at -$2.39. Price movements for the stock have been influenced by the stock’s volatility, which stands at 0.60% over the week and 0.70% over the month.
Earnings per share for the fiscal year are expected to increase by 87.14%, and 54.65% over the next financial year. EPS should grow at an annualized rate of 15.00% over the next five years, compared to -66.86% over the past 5-year period.
KeyBanc Capital Markets coverage for the Avid Bioservices Inc (CDMO) stock in a research note released on March 14, 2023 offered a Overweight rating with a price target of $20. KeyBanc Capital Markets was of a view on December 08, 2021 that the stock is Sector Weight, while RBC Capital Mkts gave the stock Outperform rating on March 17, 2021, issuing a price target of $21. KeyBanc Capital Markets on their part issued Overweight rating on November 10, 2020.
